本文選題：艾拉莫德 + 甲氨蝶呤�。� 參考：《中國藥房》2017年32期

【摘要】：目的:觀察艾拉莫德聯(lián)合甲氨蝶呤治療類風(fēng)濕性關(guān)節(jié)炎的臨床療效及安全性。方法:選擇2015年2月-2016年2月于我院接受治療的82例類風(fēng)濕性關(guān)節(jié)炎患者,采用隨機(jī)數(shù)字表法分為觀察組和對照組,各41例。對照組患者給予甲氨蝶呤片10 mg口服,每周1次,2周后逐漸增至15 mg,每周1次。觀察組患者在對照組基礎(chǔ)上給予艾拉莫德片25 mg餐后口服,bid。兩組患者的療程均為6個(gè)月。觀察兩組患者的臨床療效、不良反應(yīng)發(fā)生情況和治療前后的關(guān)節(jié)壓痛數(shù)、關(guān)節(jié)腫脹數(shù)、晨僵時(shí)間;檢測兩組患者治療前后的紅細(xì)胞沉降率、C反應(yīng)蛋白(CRP)、血小板計(jì)數(shù)、血清免疫球蛋白(IgG、IgA、IgM)和T淋巴細(xì)胞亞群(CD3~+、CD4~+、CD8~+)水平。結(jié)果:觀察組患者臨床總有效率為90.24%,明顯高于對照組的78.05%,差異有統(tǒng)計(jì)學(xué)意義(P0.05)。治療前,兩組患者上述指標(biāo)水平比較,差異均無統(tǒng)計(jì)學(xué)意義(P0.05)。治療后,兩組患者的關(guān)節(jié)壓痛數(shù)、關(guān)節(jié)腫脹數(shù)明顯少于治療前,晨僵時(shí)間明顯短于治療前,紅細(xì)胞沉降率、CRP、血小板計(jì)數(shù)、血清免疫球蛋白和T淋巴細(xì)胞亞群水平均明顯低于治療前,且觀察組均明顯低于對照組,差異均有統(tǒng)計(jì)學(xué)意義(P0.05)。兩組患者均未見嚴(yán)重的不良反應(yīng)發(fā)生,組間不良反應(yīng)發(fā)生率比較,差異無統(tǒng)計(jì)學(xué)意義(P0.05)。結(jié)論:艾拉莫德聯(lián)合甲氨蝶呤較單用甲氨蝶呤更能夠提高療效、緩解患者臨床癥狀、抑制患者免疫功能,從而控制類風(fēng)濕性關(guān)節(jié)炎的疾病進(jìn)展,且安全性較好。
[Abstract]:Objective: to observe the efficacy and safety of iramod combined with methotrexate in the treatment of rheumatoid arthritis. Methods: 82 patients with rheumatoid arthritis who were treated in our hospital from February 2015 to February 2016 were randomly divided into two groups: observation group (n = 41) and control group (n = 41). Patients in the control group were given 10 mg methotrexate orally, and gradually increased to 15 mg once a week after 2 weeks. The patients in the observation group were treated with 25 mg elamod tablets after meal oral administration on the basis of the control group. The course of treatment was 6 months in both groups. The clinical efficacy, adverse reactions, number of joint tenderness, joint swelling and morning stiffness before and after treatment were observed, the erythrocyte sedimentation rate and C-reactive protein (CRP) and platelet count were measured before and after treatment. The levels of serum immunoglobulin (IgG) and T lymphocyte subsets (CD3 ~ + CD4 ~ + CD8 ~) were measured. Results: the total clinical effective rate of the observation group was 90.24, which was significantly higher than that of the control group (78.05). The difference was statistically significant (P0.05). Before treatment, the two groups of patients compared the above indicators, the difference was not statistically significant (P0.05). After treatment, the number of joint tenderness and joint swelling in both groups were significantly less than those before treatment, the time of morning stiffness was significantly shorter than that before treatment, and the erythrocyte sedimentation rate and platelet count were lower than those before treatment. The levels of serum immunoglobulin and T lymphocyte subsets were significantly lower in the observation group than in the control group (P0.05). No serious adverse reactions occurred in the two groups, and there was no significant difference in the incidence of adverse reactions between the two groups (P0.05). Conclusion: Elamod combined with methotrexate is more effective than methotrexate alone in relieving clinical symptoms and inhibiting the immune function of patients so as to control the progression of rheumatoid arthritis and its safety is better than that of methotrexate alone.
【作者單位】： 萊蕪市人民醫(yī)院藥劑科;萊蕪市人民醫(yī)院內(nèi)科;
【分類號】：R593.22

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 張昆鵬;甲氨蝶呤在日本導(dǎo)致134例患者死亡[J];基層醫(yī)學(xué)論壇;2005年03期

2 曹雙全;;對甲氨蝶呤治療炎性關(guān)節(jié)炎的評價(jià)[J];國外醫(yī)藥.合成藥.生化藥.制劑分冊;1987年05期

3 張燕;;甲氨蝶呤過量致便血1例[J];中國中西醫(yī)結(jié)合消化雜志;2006年03期

4 李進(jìn)峰;閆秀娟;張媛;;甲氨蝶呤引起急性肝損傷1例[J];北方藥學(xué);2013年11期

5 何曉瑾;金實(shí);;痛痹方聯(lián)合甲氨蝶呤治療活動期類風(fēng)濕性關(guān)節(jié)炎30例臨床研究[J];江蘇中醫(yī)藥;2007年02期

6 楊俊華,鄭金聰;甲氨蝶呤臨床新用途[J];新醫(yī)學(xué);1991年11期

7 路杰;許勇芝;唐德q，

本文編號：2093952